OncoNexus(@Onco_Nexus):How has systemic therapy changed the role of TACE in intermediate-stage HCC? In this episode from @TheGutOncLab , Dr. Mark Yarchoan (@MarkYarchoan) joins Drs. Nicholas Hornstein (@GIMedOnc), Timothy Brown, MD MSCE (@TimothyJBrownMD), & Udhay Singh Grewal, MD (@UGrewalMD) to discuss the evolving role of TACE alongside systemic therapy in HCC and what recent combination data may mean for treatment selection and sequencing. As immunotherapy-based regimens move earlier in the treatment landscape, the group explores where TACE still fits, which patients may benefit most from a combined approach, and how practice could continue to evolve. Watch the full discussion on Oncology Nexus:

2026.08.07 18:27

How has systemic therapy changed the role of TACE in intermediate-stage HCC? In this episode from @TheGutOncLab , Dr. Mark Yarchoan (@MarkYarchoan) joins Drs. Nicholas Hornstein (@GIMedOnc), Timothy Brown, MD MSCE (@TimothyJBrownMD), & Udhay Singh Grewal, MD (@UGrewalMD) to discuss the evolving role of TACE alongside systemic therapy in HCC and what recent combination data may mean for treatment selection and sequencing. As immunotherapy-based regimens move earlier in the treatment landscape, the group explores where TACE still fits, which patients may benefit most from a combined approach, and how practice could continue to evolve. Watch the full discussion on Oncology Nexus: